Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
![The ATLAS ACS 2-TIMI 51 trial [11] | Download Table](https://www.researchgate.net/publication/262845959/figure/tbl1/AS:670449130295299@1536858937293/The-ATLAS-ACS-2-TIMI-51-trial-11.png "The ATLAS ACS 2-TIMI 51 trial [11] | Download Table")
The ATLAS ACS 2-TIMI 51 trial [11] | Download Table
Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51 | tctmd.com
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure1-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
NOACS: Emerging data in ACS/IHD - ppt download
Unmet Needs in the Secondary Prevention in ACS: The Dual Pathway Approach (Transcript)
60004-2.fp.png "RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology")
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology
ATLAS ACS 2-TIMI 51: Efficacy Endpoints: Very Low-Dose 2.5 mg BID - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Dia 1
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure2-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
ATLAS ACS 2-TIMI 51: Statistical Analysis Pre-specified Primary Efficacy Analysis - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
PPT - ATLAS ACS-TIMI 46 PowerPoint Presentation, free download - ID:5581682
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/5-Figure4-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
PPT - C. Michael Gibson, MS, MD on behalf of the ATLAS ACS 2 TIMI 51 Investigators PowerPoint Presentation - ID:1519803
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial - The Lancet
Dia 1
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
figure26_large.png
